Discover

SRRK
Scholar Rock Holding Corporation
46.65
2 x 34.58
2 x 58.79
bid
ask
-
2.37
4.83%
2 @ 07:49 PM
47.00 +0.35 (0.75%)
Ytd5.90%
1y43.63%
45.88
day range
48.52
27.92
52 week range
60.04
Open48.02Prev Close49.02Low45.88High48.52Mkt Cap5.68B
Vol3.25MAvg Vol1.49MEPS-3.31P/EN/AForward P/E-18.26
Beta0.68Short Ratio17.04Inst. Own117.60%DividendN/ADiv YieldN/A
Ex Div DateN/AEarning11-1250-d Avg53.10200-d Avg48.201yr Est69.94

SRRK News

Scholar Rock Holding Corporation $SRRK Shares Bought by Engineers Gate Manager LP
defenseworld.net
Scholar Rock Holding Corporation $SRRK Shares Bought by Engineers Gate Manager LP

Engineers Gate Manager LP lifted its stake in shares of Scholar Rock Holding Corporation (NASDAQ: SR

Scholar Rock: Reiterating 'Strong Buy' On FDA Approval SMA And Expansions Now In Play
seekingalpha.com
Scholar Rock: Reiterating 'Strong Buy' On FDA Approval SMA And Expansions Now In Play

Scholar Rock Holding Corporation maintains a "Strong Buy" rating following FDA approval of ISEMBYLD

benzinga.com
Evercore ISI Group Maintains Outperform on Scholar Rock Holding, Raises Price Target to $72

Evercore ISI Group analyst Cory Kasimov maintains Scholar Rock Holding (NASDAQ:SRRK) with a Outpe

benzinga.com
Piper Sandler Maintains Overweight on Scholar Rock Holding, Raises Price Target to $75

Piper Sandler analyst Allison Bratzel maintains Scholar Rock Holding (NASDAQ:SRRK) with a Overwei

benzinga.com
Jefferies Maintains Buy on Scholar Rock Holding, Raises Price Target to $65

Jefferies analyst Amy Li maintains Scholar Rock Holding (NASDAQ:SRRK) with a Buy and raises the p

This Cellectis Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday
benzinga.com
This Cellectis Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday

Analysts downgraded Banco Santander Brasil, Ribbon Communications, Cellectis, Scholar Rock, with mix

benzinga.com
Wedbush Maintains Outperform on Scholar Rock Holding, Raises Price Target to $70

Wedbush analyst David Nierengarten maintains Scholar Rock Holding (NASDAQ:SRRK) with a Outperform

Zebra Technologies To Rally Around 24%? Here Are 10 Top Analyst Forecasts For Tuesday
benzinga.com
Zebra Technologies To Rally Around 24%? Here Are 10 Top Analyst Forecasts For Tuesday

Analysts cut Exodus’ target, raised targets for Teledyne, Roblox, Scholar Rock, Zebra, Agilon, SM En

benzinga.com
Barclays Downgrades Scholar Rock Holding to Equal-Weight, Raises Price Target to $58

Barclays analyst Etzer Darout downgrades Scholar Rock Holding (NASDAQ:SRRK) from Overweight to Eq

Here Are Tuesday’s Top Wall Street Analyst Research Calls: Autodesk, Eli Lilly, Etsy, Lear, Netskope, Nokia, Northrop Grumman, Rapid7, Rivian Automotive, Ulta Beauty, and More
247wallst.com
Here Are Tuesday’s Top Wall Street Analyst Research Calls: Autodesk, Eli Lilly, Etsy, Lear, Netskope

Markets are rattled ahead of Wednesday's Fed decision, and Wall Street analysts are making bold move

benzinga.com
HC Wainwright & Co. Maintains Buy on Scholar Rock Holding, Raises Price Target to $70

HC Wainwright & Co. analyst Andres Y. Maldonado maintains Scholar Rock Holding (NASDAQ:SRRK)

Scholar Rock Holding Corporation (SRRK) Discusses FDA Approval and Clinical Impact of ISEMBYLD in SMA Treatment Transcript
seekingalpha.com
Scholar Rock Holding Corporation (SRRK) Discusses FDA Approval and Clinical Impact of ISEMBYLD in SM

Scholar Rock Holding Corporation (SRRK) Discusses FDA Approval and Clinical Impact of ISEMBYLD in SM

benzinga.com
Raymond James Maintains Strong Buy on Scholar Rock Holding, Raises Price Target to $72

Raymond James analyst Gary Nachman maintains Scholar Rock Holding (NASDAQ:SRRK) with a Strong Buy

benzinga.com
BMO Capital Maintains Outperform on Scholar Rock Holding, Raises Price Target to $84

BMO Capital analyst Etzer Darout maintains Scholar Rock Holding (NASDAQ:SRRK) with a Outperform a

benzinga.com
Truist Securities Reiterates Buy on Scholar Rock Holding, Raises Price Target to $76

Truist Securities analyst Srikripa Devarakonda reiterates Scholar Rock Holding (NASDAQ:SRRK) with

benzinga.com
Citigroup Maintains Buy on Scholar Rock Holding, Raises Price Target to $74

Citigroup analyst Geoff Meacham maintains Scholar Rock Holding (NASDAQ:SRRK) with a Buy and raise

Scholar Rock Marks 'Defining Moment' with First Muscle-Targeted Treatment for Spinal Muscular Atrophy
benzinga.com
Scholar Rock Marks 'Defining Moment' with First Muscle-Targeted Treatment for Spinal Muscular Atroph

The U.S. Food and Drug Administration on Friday approved ISEMBYLD (apitegromab-mstn) from Scholar Ro

Scholar Rock Marks 'Defining Moment' with First Muscle-Targeted Treatment for Spinal Muscular Atrophy
benzinga.com
Scholar Rock Marks 'Defining Moment' with First Muscle-Targeted Treatment for Spinal Muscular Atroph

FDA approves Scholar Rock Isembyld to treat spinal muscular atrophy in adults and pediatric patients

benzinga.com
Wedbush Reiterates Outperform on Scholar Rock Holding, Maintains $64 Price Target

Wedbush analyst David Nierengarten reiterates Scholar Rock Holding (NASDAQ:SRRK) with a Outperfor

Scholar Rock prices first drug to target SMA muscle loss at $11,659 per vial
reuters.com
Scholar Rock prices first drug to target SMA muscle loss at $11,659 per vial

Scholar Rock on Monday ​set a list ‌price of $11,659 per single-use vial ​for its ​newly approved sp

Why Scholar Rock Shares Are Trading Higher By Around 12%; Here Are 20 Stocks Moving Premarket
benzinga.com
Why Scholar Rock Shares Are Trading Higher By Around 12%; Here Are 20 Stocks Moving Premarket

Shares of Scholar Rock Holding Corp (NASDAQ:SRRK) rose sharply in pre-market trading after the compa

Why Scholar Rock Shares Are Trading Higher By Around 12%; Here Are 20 Stocks Moving Premarket
benzinga.com
Why Scholar Rock Shares Are Trading Higher By Around 12%; Here Are 20 Stocks Moving Premarket

Scholar Rock surged 11.9% after FDA approved ISEMBYLD for SMA; Scinai, Intercont and Rum led premark

Scholar Rock Announces FDA Approval of ISEMBYLD™ (apitegromab-mstn), the First and Only Muscle-Targeted Treatment for Children and Adults with Spinal Muscular Atrophy (SMA)
businesswire.com
Scholar Rock Announces FDA Approval of ISEMBYLD™ (apitegromab-mstn), the First and Only Muscle-Targe

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a global biopharmaceutical company d

US FDA approves Scholar Rock's muscle weakness drug
reuters.com
US FDA approves Scholar Rock's muscle weakness drug

The ​U.S. Food ‌and Drug ​Administration ​on Friday ⁠approved ​Scholar ​Rock's therapy to ​treat ​a

Scholar Rock Holding Corporation (SRRK) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript
seekingalpha.com
Scholar Rock Holding Corporation (SRRK) Presents at Citigroup's Biopharma Back to School Summit 2026

Scholar Rock Holding Corporation (SRRK) Presents at Citigroup's Biopharma Back to School Summit 2026

benzinga.com
HC Wainwright & Co. Reiterates Buy on Scholar Rock Holding, Maintains $65 Price Target

HC Wainwright & Co. analyst Andres Y. Maldonado reiterates Scholar Rock Holding (NASDAQ:SRRK)

Scholar Rock: Manufacturing Noise Obscures A Muscle-Targeted Franchise
seekingalpha.com
Scholar Rock: Manufacturing Noise Obscures A Muscle-Targeted Franchise

Scholar Rock is positioned to launch apitegromab as the first muscle-targeted therapy for SMA, pendi

benzinga.com
Scholar Rock Receives FDA's Fast Track And Orphan Drug Designations For Apitegromab To Treat Faciosc

Scholar Rock (NASDAQ: SRRK), a global biopharmaceutical company dedicated to improving the lives of

Scholar Rock Receives FDA Fast Track Designation for Apitegromab Facioscapulohumeral Muscular Dystrophy (FSHD) Program as Participant Dosing Commences in Phase 2 FORGE Trial
businesswire.com
Scholar Rock Receives FDA Fast Track Designation for Apitegromab Facioscapulohumeral Muscular Dystro

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a global biopharmaceutical company d

Beaconlight Capital LLC Makes New Investment in Scholar Rock Holding Corporation $SRRK
defenseworld.net
Beaconlight Capital LLC Makes New Investment in Scholar Rock Holding Corporation $SRRK

Beaconlight Capital LLC purchased a new stake in shares of Scholar Rock Holding Corporation (NASDAQ:

9,494,084 Shares in Scholar Rock Holding Corporation $SRRK Purchased by BlackRock Inc.
defenseworld.net
9,494,084 Shares in Scholar Rock Holding Corporation $SRRK Purchased by BlackRock Inc.

BlackRock Inc. acquired a new position in shares of Scholar Rock Holding Corporation (NASDAQ: SRRK)

benzinga.com
Scholar Rock Removes Catalent Indiana As Commercial Fill-Finish Facility From Its Apitegromab BLA Fo

FDA review of BLA progressing well with Scholar Rock’s alternate fill-finish facilityCompany is prep

Scholar Rock Provides Update on Global Apitegromab Regulatory Progress Across U.S., Europe, and Japan
businesswire.com
Scholar Rock Provides Update on Global Apitegromab Regulatory Progress Across U.S., Europe, and Japa

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a global biopharmaceutical company d

Scholar Rock Eyes Sept. 30 FDA Decision for SMA Drug Apitegromab
marketbeat.com
Scholar Rock Eyes Sept. 30 FDA Decision for SMA Drug Apitegromab

Scholar Rock NASDAQ: SRRK CEO David Hallal said the company is preparing for a September 30 FDA deci

Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
businesswire.com
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK; the “Company”) today announced that t

benzinga.com
JP Morgan Maintains Overweight on Scholar Rock Holding, Raises Price Target to $63

JP Morgan analyst Tessa Romero maintains Scholar Rock Holding (NASDAQ:SRRK) with a Overweight and

Scholar Rock Overcomes Manufacturing Hurdle to Keep Lead Drug FDA Review on Schedule
benzinga.com
Scholar Rock Overcomes Manufacturing Hurdle to Keep Lead Drug FDA Review on Schedule

Scholar Rock shifts its FDA review for SMA treatment apitegromab to a secondary facility, keeping th

benzinga.com
Wedbush Reiterates Outperform on Scholar Rock Holding, Maintains $58 Price Target

Wedbush analyst David Nierengarten reiterates Scholar Rock Holding (NASDAQ:SRRK) with a Outperfor

benzinga.com
HC Wainwright & Co. Reiterates Buy on Scholar Rock Holding, Maintains $65 Price Target

HC Wainwright & Co. analyst Andres Y. Maldonado reiterates Scholar Rock Holding (NASDAQ:SRRK)

Scholar Rock drops Catalent facility from marketing application for muscle weakness drug
reuters.com
Scholar Rock drops Catalent facility from marketing application for muscle weakness drug

Scholar Rock said on Friday it would remove Catalent's Indiana manufacturing facility from its appli

benzinga.com
Citigroup Maintains Buy on Scholar Rock Holding, Raises Price Target to $60

Citigroup analyst Geoff Meacham maintains Scholar Rock Holding (NASDAQ:SRRK) with a Buy and raise

benzinga.com
Scholar Rock Removes Catalent Indiana From Apitegromab BLA After FDA OAI Classification; FDA Review

Today, August 7, 2026, Scholar Rock received customer notification from Catalent Indiana LLC (part o

Scholar Rock Announces FDA Review of Apitegromab Biologics License Application (BLA) for Spinal Muscular Atrophy (SMA) to Progress with Second Fill-Finish Facility; Approval Decision Anticipated by September 30, 2026 Action Date
businesswire.com
Scholar Rock Announces FDA Review of Apitegromab Biologics License Application (BLA) for Spinal Musc

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a global biopharmaceutical company d

Scholar Rock Q2 Earnings Call Highlights
marketbeat.com
Scholar Rock Q2 Earnings Call Highlights

Scholar Rock NASDAQ: SRRK said its resubmitted biologics license application for apitegromab remains

benzinga.com
Scholar Rock Holding Q2 EPS $(0.84) Beats $(0.85) Estimate; Cash Balance Of $492M

Scholar Rock Holding (NASDAQ:SRRK) reported quarterly losses of $(0.84) per share which beat the ana

benzinga.com
Wedbush Reiterates Outperform on Scholar Rock Holding, Maintains $58 Price Target

Wedbush analyst David Nierengarten reiterates Scholar Rock Holding (NASDAQ:SRRK) with a Outperfor

benzinga.com
Scholar Rock Announces European Medicines Agency Reviewing Apitegromab Marketing Authorisation Appli

Scholar Rock (NASDAQ: SRRK), a global biopharmaceutical company dedicated to improving the lives of

benzinga.com
Barclays Maintains Overweight on Scholar Rock Holding, Raises Price Target to $55

Barclays analyst Etzer Darout maintains Scholar Rock Holding (NASDAQ:SRRK) with a Overweight and

benzinga.com
HC Wainwright & Co. Maintains Buy on Scholar Rock Holding, Raises Price Target to $65

HC Wainwright & Co. analyst Andres Y. Maldonado maintains Scholar Rock Holding (NASDAQ:SRRK)

benzinga.com
Canaccord Genuity Initiates Coverage On Scholar Rock Holding with Buy Rating, Announces Price Target

Canaccord Genuity analyst Gary Nachman initiates coverage on Scholar Rock Holding (NASDAQ:SRRK) w